FirstHealth of the Carolinas

Clinical Trial Details

Study Title: SWOG 1115: Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy
Study Type: Interventional
Study Condition: Pancreatic Cancer
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Lori DeSpain
Phone: (910) 715-2200
Eligibility Criteria: Women and men ages 18 and older, diagnosed with metastatic pancreatic cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Southwest Oncology Group
Study Rationale: Selumetinib and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such asoxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet know whether selumetinib and Akt inhibitor MK2206 are more effective than oxaliplatin and fluorouracil in treating patients with metastatic pancreatic cancer.
Study Purpose: This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to mFOLFOX therapy in treating patients with metastatic pancreatic cancer previously treated with chemotherapy.
Study Link: http://clinicaltrials.gov/show/NCT01658943
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.